In a phase 3 clinical trial, liraglutide was shown to reduce the body mass index in children ages 6 to 11 with obesity, according to a study published Sept. 10 in The New England Journal of Medicine.

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study suggested. Among more than 200,000 individuals with AUD, those taking ...

Semaglutide and liraglutide also linked to reduction in risks for SUD hospitalization, somatic hospitalizations. (HealthDay News) — Semaglutide and liraglutide are associated with a reduced risk for ...

DENVER — A weight-loss drug used to treat obesity and diabetes has shown promise to treat another disorder: opioid addiction. Early results from a small clinical trial, presented February 17 at the ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Novo Nordisk ($NVO) has a date with an FDA advisory panel. The subject: Its blockbuster diabetes drug liraglutide, which it's hoping to rebrand into an obesity ...

This article was reviewed by Lynn Marie Morski, MD, JD Key Takeaways: Peptides are compounds made of amino acids linked by ...

ORLANDO, FL— The glucagonlike peptide-1 (GLP-1) receptor agonist liraglutide (Victoza, Novo Nordisk) did not improve clinical stability at 6 months in 300 patients with advanced heart failure (HF) and ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...